Research & Literature

A woman with rare blastic plasmacytoid dendritic cell neoplasm on the face.

Huang YY, Liu YR, Li K, et al.

Oral surgery, oral medicine, oral pathology and oral radiology 2016; (121(1)):e16-8.

BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM --A RAPIDLY EVOLVING ENTITY. CASE REPORT.

Andrese E, Solovăstru LG, Dimofte G, et al.

Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 2015; (119(2)):379-83.

Recurrent undifferentiated shock: Idiopathic Systemic Capillary Leak Syndrome.

Aroney N, Ure S, White H, Sane S

Clinical case reports 2015; (3(7)):527-30 doi:10.1002/ccr3.280.

Systemic Capillary Leak Syndrome after Influenza Vaccination in a Peritoneal Dialysis Patient.

Geerse DA, Meynen FM, Gelens MA, et al.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 2015; (35(7)):772-3 doi:10.3747/pdi.2014.00194.

Myeloid Cell Nuclear Differentiation Antigen (MNDA) Expression Distinguishes Extramedullary Presentations of Myeloid Leukemia From Blastic Plasmacytoid Dendritic Cell Neoplasm.

Johnson RC, Kim J, Natkunam Y, et al.

The American journal of surgical pathology 2016; (40(4)):502-9 doi:10.1097/PAS.0000000000000595.

Severe cerebral involvement due to idiopathic systemic capillary leak syndrome.

Günes AR, Berlit P, Weber R

Clinical case reports 2016; (4(4)):429-31 doi:10.1002/ccr3.525.

Blastic plasmacytoid dendritic cell neoplasm.

Pemmaraju N

Clinical advances in hematology & oncology : H&O 2016; (14(4)):220-2.

Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Pemmaraju N, Gupta V, Thompson MA, Lane AA

Current hematologic malignancy reports 2016; (11(6)):462-467 doi:10.1007/s11899-016-0340-3.

An Unexpected Chink in the Transcriptional Armor of Plasmacytoid Dendritic Neoplasms.

Kleppe M, Levine RL

Cancer cell 2016; (30(5)):659-660 doi:10.1016/j.ccell.2016.10.016.

[Blastic plasmacytoid dendritic cell neoplasm with complete clinical remission with chemotherapy and central nervous system relapse: Report of one case].

Contreras L, Mercado L, Delgado C, et al.

Revista medica de Chile 2017; (145(1)):115-120 doi:10.4067/S0034-98872017000100015.

Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors.

Villani AC, Satija R, Reynolds G, et al.

Science (New York, N.Y.) 2017; (356(6335)) doi:10.1126/science.aah4573.

Childhood Blastic Plasmacytoid Dendritic Cell Neoplasm Mimicking Acute Rheumatic Fever: Report of an Unusual Clinical Presentation and Review of Literature.

Rajkumari BD, Munikoty V, Sreedharanunni S, et al.

Journal of pediatric hematology/oncology 2018; (40(5)):e327-e329 doi:10.1097/MPH.0000000000000951.

[Clinical characteristics of 6 patients with blastic plasmacytoid dendritic cell neoplasm].

Han X, Ouyang MQ, Pei Q, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2017; (38(8)):700-705 doi:10.3760/cma.j.issn.0253-2727.2017.08.010.

Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

Zeiser R, Blazar BR

The New England journal of medicine 2017; (377(22)):2167-2179 doi:10.1056/NEJMra1609337.

Blastic plasmacytoid dendritic cell neoplasm.

Rai MP, Bedi PS, Kandola SK, et al.

Clinical case reports 2018; (6(4)):770-772 doi:10.1002/ccr3.1457.

Utility of tissue elafin as an immunohistochemical marker for diagnosis of acute skin graft-versus-host disease: a pilot study.

Mahabal GD, George L, Peter D, et al.

Clinical and experimental dermatology 2019; (44(2)):161-168 doi:10.1111/ced.13678.

The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.

Kerr D, Sokol L

Expert opinion on investigational drugs 2018; (27(9)):733-739 doi:10.1080/13543784.2018.1512970.

Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate.

Sato S, Tanaka E, Tamai Y

Annals of hematology 2019; (98(3)):801-803 doi:10.1007/s00277-019-03611-3.

Blastic Plasmacytoid Dendritic Cell Neoplasm; A Report of Three Cases.

Safaei A, Monabati A, Mokhtari M, et al.

Iranian journal of medical sciences 2019; (44(1)):74-78.

Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report.

Iversen KF, Holdgaard PC, Preiss B, et al.

Haematologica 2019; (104(9)):e432-e433 doi:10.3324/haematol.2018.214635.

Germline missense NF1 mutation in an elderly patient with a blastic plasmacytoid dendritic cell neoplasm.

Szczepaniak A, Machnicki M, Gniot M, et al.

International journal of hematology 2019; (110(1)):102-106 doi:10.1007/s12185-019-02642-w.

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

Pemmaraju N, Lane AA, Sweet KL, et al.

The New England journal of medicine 2019; (380(17)):1628-1637 doi:10.1056/NEJMoa1815105.

Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects.

Sapienza MR, Pileri A, Derenzini E, et al.

Cancers 2019; (11(5)) doi:10.3390/cancers11050595.

Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm.

Sukswai N, Aung PP, Yin CC, et al.

The American journal of surgical pathology 2019; (43(10)):1429-1437 doi:10.1097/PAS.0000000000001316.

Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.

Economides MP, McCue D, Lane AA, Pemmaraju N

Expert review of clinical pharmacology 2019; (12(10)):941-946 doi:10.1080/17512433.2019.1662297.

The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm.

Marmouset V, Joris M, Merlusca L, et al.

Hematological oncology 2019; (37(4)):487-489 doi:10.1002/hon.2671.

Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.

Economides MP, Konopleva M, Pemmaraju N

Therapeutic advances in hematology 2019; (10()):2040620719874733 doi:10.1177/2040620719874733.

An Unusual Manifestation of Blastic Plasmacytoid Dendritic Cell Neoplasm as a Testicular Tumor.

Pak DM, Tretiakova MS

Case reports in pathology 2019; (2019()):9196167 doi:10.1155/2019/9196167.

Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Alfayez M, Konopleva M, Pemmaraju N

Expert opinion on biological therapy 2020; (20(2)):115-123 doi:10.1080/14712598.2020.1701651.

Blastic plasmacytoid dendritic cell neoplasm: diagnosis, manifestations, and treatment.

Sweet K

Current opinion in hematology 2020; (27(2)):103-107 doi:10.1097/MOH.0000000000000569.

Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm.

Wang W, Khoury JD, Miranda RN, et al.

Haematologica 2021; (106(4)):1047-1055 doi:10.3324/haematol.2020.247569.

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report and Clinicopathological Review.

Zaki MMAF, Zalata K, El-Hawary AK, et al.

Journal of hematology 2018; (7(3)):124-127 doi:10.14740/jh428w.

Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Presentation and Diagnosis.

Deconinck E, Petrella T, Garnache Ottou F

Hematology/oncology clinics of North America 2020; (34(3)):491-500 doi:10.1016/j.hoc.2020.01.010.

Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm.

Hammond D, Pemmaraju N

Hematology/oncology clinics of North America 2020; (34(3)):565-574 doi:10.1016/j.hoc.2020.01.005.

Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.

Xue T, Budde LE

Hematology/oncology clinics of North America 2020; (34(3)):575-587 doi:10.1016/j.hoc.2020.01.006.

Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm.

Kharfan-Dabaja MA, Cherry M

Hematology/oncology clinics of North America 2020; (34(3)):621-629 doi:10.1016/j.hoc.2020.01.009.

Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.

Lee SS, McCue D, Pemmaraju N

Expert review of anticancer therapy 2020; (20(7)):543-550 doi:10.1080/14737140.2020.1776120.

Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.

Beziat G, Ysebaert L

OncoTargets and therapy 2020; (13()):5199-5205 doi:10.2147/OTT.S228342.

Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant.

Yun S, Chan O, Kerr D, et al.

Blood advances 2020; (4(14)):3435-3442 doi:10.1182/bloodadvances.2020001875.

Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.

Pemmaraju N, Konopleva M

Blood advances 2020; (4(16)):4020-4027 doi:10.1182/bloodadvances.2019000173.

Targeting CD123 in AML.

Lane AA

Clinical lymphoma, myeloma & leukemia 2020; (20 Suppl 1()):S67-S68 doi:10.1016/S2152-2650(20)30466-3.

Sjögren's syndrome concurrent with organizing pneumonia with secondary systemic capillary leak syndrome: a case report.

Cao C, Shao Q, Yang H

Scandinavian journal of rheumatology 2021; (50(4)):322-324 doi:10.1080/03009742.2020.1774648.

Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients.

Laribi K, Baugier de Materre A, Sobh M, et al.

Blood advances 2020; (4(19)):4838-4848 doi:10.1182/bloodadvances.2020002474.

A Very Rare Type of Leukemia in a Young Pediatric Patient Treated With Hematopoietic Stem Cell Transplantation: Blastic Plasmacytoid Dendritic Cell Neoplasm.

Tekkeşin F, Asarcikli F, Yildirim ÜM, et al.

Journal of pediatric hematology/oncology 2021; (43(2)):e288-e291 doi:10.1097/MPH.0000000000001999.

Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report.

Dang X, Zhou D, Meng L, Bi L

The Journal of international medical research 2021; (49(2)):300060520982667 doi:10.1177/0300060520982667.

SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4.

Onodi F, Bonnet-Madin L, Meertens L, et al.

The Journal of experimental medicine 2021; (218(4)) doi:10.1084/jem.20201387.

Spontaneous Regression of Blastic Plasmacytoid Dendritic Cell Neoplasm Following Sepsis by Serratia marcescens: A Case Report and Literature Review.

Suzuki A, Abe S, Koyama K, et al.

Internal medicine (Tokyo, Japan) 2021; (60(6)):927-933 doi:10.2169/internalmedicine.5820-20.

Tagraxofusp Treatment: Implications for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.

Morin A, Kechedjian F, Walton P, Tavakoli A

Clinical journal of oncology nursing 2021; (25(2)):E10-E16 doi:10.1188/21.CJON.E10-E16.

A misdiagnosed case of blastic plasmacytoid dendritic cell neoplasm experiencing multiple recurrences who underwent allogeneic stem cell transplantation: a case report.

Salemi F, Mortazavizadeh SMR, Mirmoeeni S, et al.

Journal of medical case reports 2021; (15(1)):292 doi:10.1186/s13256-021-02860-z.

Targeting CD123 in BPDCN: an emerging field.

DiPippo AJ, Wilson NR, Pemmaraju N

Expert review of hematology 2021; (14(11)):993-1004 doi:10.1080/17474086.2021.1988848.

Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Bashir Q, Milton DR, Popat UR, et al.

Bone marrow transplantation 2022; (57(1)):51-56 doi:10.1038/s41409-021-01478-5.

Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Yin CC, Pemmaraju N, You MJ, et al.

Cancers 2021; (13(23)) doi:10.3390/cancers13235888.

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD.

Pemmaraju N, Wilson NR, Garcia-Manero G, et al.

Blood advances 2022; (6(10)):3027-3035 doi:10.1182/bloodadvances.2021006645.

Human genetic and immunological determinants of critical COVID-19 pneumonia.

Zhang Q, Bastard P, , et al.

Nature 2022; (603(7902)):587-598 doi:10.1038/s41586-022-04447-0.

A rare case report of graft-versus-host disease-related cutaneous horns of the lower lip.

Verquin M, Politis C, Thonnart F, et al.

JAAD case reports 2022; (21()):59-62 doi:10.1016/j.jdcr.2021.12.035.

Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.

Abla D, Abboud MR, Noun D, et al.

Leukemia research reports 2022; (17()):100313 doi:10.1016/j.lrr.2022.100313.

Blastic Plasmacytoid Dendritic Cell Neoplasm With Central Nervous System Involvement: A Case Report.

Molina Castro D, Perilla Suárez O, Cuervo-Sierra J, Moreno A

Cureus 2022; (14(4)):e23888 doi:10.7759/cureus.23888.

Two cases of blastic plasmacytoid dendritic cell neoplasm.

Hong AS, Alsharabati M, Jagun O, et al.

International journal of dermatology 2022; (61(10)):e405-e407 doi:10.1111/ijd.16256.

Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study.

Lu Y, Sun RJ, Zhang JP, et al.

Leukemia & lymphoma 2022; (63(13)):3092-3099 doi:10.1080/10428194.2022.2118531.

An Analysis of the Pathologic Features of Blastic Plasmacytoid Dendritic Cell Neoplasm Based on a Comprehensive Literature Database of Cases.

Ohgami RS, Aung PP, Gru AA, et al.

Archives of pathology & laboratory medicine 2023; (147(7)):837-846 doi:10.5858/arpa.2021-0612-RA.

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.

Pemmaraju N, Kantarjian H, Sweet K, et al.

Blood 2023; (141(6)):567-578 doi:10.1182/blood.2022017865.

Biallelic TET2 mutations and canonical ASXL1 mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An institutional experience and review of literature.

Zhang X, Hsi ED, Crane GM, Cheng YW

EJHaem 2023; (4(1)):236-240 doi:10.1002/jha2.617.

Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells.

Wu SJ, Sadigh S, Lane AA, Pinkus GS

American journal of clinical pathology 2023; (159(5)):455-463 doi:10.1093/ajcp/aqac174.

Top Ten Lymphoproliferative Lesions Not to Miss When Evaluating Oral Ulcer Biopsies.

Hyrcza MD, Lindenmuth TR, Auerbach A

Head and neck pathology 2023; (17(1)):99-118 doi:10.1007/s12105-023-01532-2.

Blastic Plasmacytoid Dendritic Cell Neoplasm.

Jain A, Sweet K

Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(5)):515-521 doi:10.6004/jnccn.2023.7026.

Topical treatment of oral chronic graft-versus-host- disease in hematopoietic stem cell transplant recipients: A systematic review.

Haas L, Cruz-Pamplona M

Journal of clinical and experimental dentistry 2023; (15(5)):e420-e427 doi:10.4317/jced.60138.

Comparison and Development of Immunohistochemical Diagnostic Criteria for Blastic Plasmacytoid Dendritic Cell Neoplasm.

Sakamoto K, Baba S, Okumura Y, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2023; (36(10)):100253 doi:10.1016/j.modpat.2023.100253.

[Chemotherapy Combined with Venetoclax Followed by Allo-Hematopoietic Stem Cell Transplantation for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm].

Cheng P, Wang LL, Wang QX, et al.

Zhongguo shi yan xue ye xue za zhi 2023; (31(5)):1531-1536 doi:10.19746/j.cnki.issn.1009-2137.2023.05.044.

Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.

Pemmaraju N, Madanat YF, Rizzieri D, et al.

Leukemia & lymphoma 2024; (65(5)):548-559 doi:10.1080/10428194.2024.2305288.

Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm.

Huang X, Wang S, Xu Y, et al.

Annals of hematology 2024; (103(6)):2165-2168 doi:10.1007/s00277-024-05749-1.

Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.

Jen WY, Konopleva M, Pemmaraju N

Cancer 2024; (130(13)):2260-2271 doi:10.1002/cncr.35315.

Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm - collected cases from a single center and case reports.

Faustmann P, Schroeder JC, Mix L, et al.

Frontiers in oncology 2024; (14()):1384172 doi:10.3389/fonc.2024.1384172.

Idiopathic Capillary Leak Syndrome (Clarkson's Disease): First Reported Case in Oman.

Al-Zaabi F, Al-Farhan H, Al-Lawati A, Al-Busaidi M

Oman medical journal 2024; (39(3)):e635 doi:10.5001/omj.2024.17.

Localized blastic plasmacytoid dendritic cell neoplasm associated with progressive clonal hematopoiesis and myelodysplastic syndrome.

Julin C, Nielsen SL, Grantzau TL, et al.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2025; (133(1)):e13486 doi:10.1111/apm.13486.

Systemic capillary leak syndrome.

Druey KM, Arnaud L, Parikh SM

Nature reviews. Disease primers 2024; (10(1)):86 doi:10.1038/s41572-024-00571-5.

Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.

Zheng JX, Betts EV, Dwyre DM, et al.

Clinical pathology (Thousand Oaks, Ventura County, Calif.) 2024; (17()):2632010X241304564 doi:10.1177/2632010X241304564.

The Challenge of Diagnosing Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.

Garg S, Dua A, Ansari A, Tabbara I

Anticancer research 2025; (45(1)):229-233 doi:10.21873/anticanres.17409.

A 31-year-old male with a plasmacytoid dendritic blast cell neoplasm.

Hernández DC, Rueda DÁ, Rapan L, et al.

Ecancermedicalscience 2024; (18()):1806 doi:10.3332/ecancer.2024.1806.

Intra-mesenteric steroids for steroid-refractory graft-versus-host disease in pediatric patients: A safe option.

Aristizábal AM, Montaña LP, Gutiérrez J, et al.

Biomedica : revista del Instituto Nacional de Salud 2024; (44(Sp. 2)):63-71 doi:10.7705/biomedica.7394.

Petechiae and a Persistent Violaceous Nodule: A Presentation of Blastic Plasmacytoid Dendritic Cell Neoplasm to Dermatology.

Anzelc M, Druskovich C, Cusick A, Franklin M

Case reports in dermatological medicine 2025; (2025()):8628105 doi:10.1155/crdm/8628105.

Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding.

Sakamoto K, Takeuchi K

Journal of clinical and experimental hematopathology : JCEH 2025; (65(1)):1-16 doi:10.3960/jslrt.24069.

Unusual Nodule on the Left Leg of an Elderly Woman-A Case Report: Challenge.

Cazzato G, Ingravallo G, Vitiello P, et al.

The American Journal of dermatopathology 2025; (47(6)):e64-e66 doi:10.1097/DAD.0000000000002961.

Single cell sequencing deciphering the heterogeneous landscape of blastic plasmacytoid dendritic cell neoplasm with novel MYB-ZFAT fusion gene.

Li R, Kuang W, Yang H, et al.

Cancer cell international 2025; (25(1)):274 doi:10.1186/s12935-025-03899-4.

Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naïve patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program.

Herling M, Angelucci E, Benoit TM, et al.

Annals of hematology 2025; (104(8)):4121-4131 doi:10.1007/s00277-025-06493-w.

Cutaneous Manifestation of a Rare Haematological Malignancy: A Case Report of the Presentation, Diagnosis, and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Hassan SL, Chatha DE

Cureus 2025; (17(7)):e87604 doi:10.7759/cureus.87604.

Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base.

Krah NM, Hoeg R, Shami PJ, et al.

Leukemia research reports 2025; (24()):100541 doi:10.1016/j.lrr.2025.100541.

Imaging findings for 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in blastic plasmacytoid dendritic cell neoplasm: case series and literature review.

Zhou Y, Li K, Jin X, et al.

Frontiers in medicine 2025; (12()):1581760 doi:10.3389/fmed.2025.1581760.

Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.

Lane AA, Papayannidis C, Angelucci E, et al.

Leukemia & lymphoma 2025; (66(14)):2569-2577 doi:10.1080/10428194.2025.2557505.

Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm.

Wang M, Xue X, Wang Z, et al.

Cancer cell international 2025; (25(1)):396 doi:10.1186/s12935-025-04038-9.

Venetoclax combined with azacitidine for treatment of a blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.

Lai Y, Chen X, Zhou H

Experimental and therapeutic medicine 2026; (31(1)):20 doi:10.3892/etm.2025.13015.

Current status and future potential of CD123-based targeted therapies for acute leukemia.

Arslan S, Aribi A, Stein A, Aldoss I

Expert opinion on biological therapy 2025; (25(12)):1299-1312 doi:10.1080/14712598.2025.2608209.

The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasm.

Azevedo RS, Nooruddin Z, Bhatia S, et al.

Expert opinion on biological therapy 2026; (26(1)):15-24 doi:10.1080/14712598.2025.2610291.